Benzenemethanol, 3-[(1R)-3-[bis(1-methylethyl)amino]-1-phenylpropyl]-4-hydroxy-
| Title | Journal |
|---|---|
| Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers. | British journal of clinical pharmacology 20110801 |
| Pharmacokinetics of tolterodine in Japanese and Koreans: physiological and stochastic assessment of ethnic differences. | Drug metabolism and pharmacokinetics 20110601 |
| Effects of hepatic dysfunction on the single-dose pharmacokinetics of fesoterodine. | Journal of clinical pharmacology 20110301 |
| Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. | The Journal of urology 20100801 |
| The pharmacokinetic profile of fesoterodine 8 mg with daytime or nighttime dosing. | European journal of clinical pharmacology 20100201 |
| The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. | Current medicinal chemistry 20090101 |
| Pharmacokinetic profile of fesoterodine. | International journal of clinical pharmacology and therapeutics 20081101 |
| Effect of the proton pump inhibitor omeprazole on the pharmacokinetics of extended-release formulations of oxybutynin and tolterodine. | Journal of clinical pharmacology 20050801 |
| Tolterodine and its active 5-hydroxymethyl metabolite: pure muscarinic receptor antagonists. | Pharmacology & toxicology 20020501 |
| The effect of tolterodine on the pharmacokinetics and pharmacodynamics of a combination oral contraceptive containing ethinyl estradiol and levonorgestrel. | Clinical therapeutics 20011101 |
| Food increases the bioavailability of tolterodine but not effective exposure. | Journal of clinical pharmacology 20010301 |